Patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN) showed no clinical benefit when treated with Amgen‘s investigative anti-interferon-gamma antibody, AMG 811, in a Phase 1b (NCT00818948) clinical trial. Some indicators of the disease dropped in response to the treatment, but less so in LN patients. The results of the clinical trial were reported in the article, “ Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis, ” published in the journal Lupus Science & Medicine .
This content is intended for informational purposes only. It should not replace professional medical advice, diagnosis, or treatment. If you think you have a medical emergency, call 911 or your doctor immediately.